Reply to: "Phase 2a randomized clinical trial of dupilumab (anti-IL-4Rα) for alopecia areata patients"

Yael Renert-Yuval^{1

2}, Emma Guttman-Yassky¹

Affiliations

¹ Department of Dermatology, and Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
² Laboratory for Investigative Dermatology, The Rockefeller University, New York, New York, USA.

Clinical Trial

Yael Renert-Yuval et al. Allergy. 2022 Jul.

. 2022 Jul;77(7):2269-2270.

doi: 10.1111/all.15285.

Yael Renert-Yuval^{1

2}, Emma Guttman-Yassky¹

¹ Department of Dermatology, and Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
² Laboratory for Investigative Dermatology, The Rockefeller University, New York, New York, USA.

No abstract available

Comment on

Correspondence to: Phase 2a randomized clinical trial of dupilumab (anti-IL-4Rα) for alopecia areata patients.
Maher E, Martiniuk F, Levis W. Maher E, et al. Allergy. 2022 Mar;77(3):1073-1074. doi: 10.1111/all.15185. Allergy. 2022. PMID: 35218045 No abstract available.

1. Maher E, Martiniuk F, Levis W. Correspondence to: phase 2a randomized clinical trial of dupilumab (anti-IL-4Ralpha) for alopecia areata patients. Allergy. 2022;77(3):1073-1074.
1. Guttman-Yassky E, Renert-Yuval Y, Bares J, et al. Phase 2a randomized clinical trial of dupilumab (anti-IL-4Ralpha) for alopecia areata patients. Allergy. 2022;77:897-906.
1. Boothby IC, Kinet MJ, Boda DP, et al. Early-life inflammation primes a T helper 2 cell-fibroblast niche in skin. Nature. 2021;599(7886):667-672.
1. Nussbaum L, Chen YL, Ogg GS. Role of regulatory T cells in psoriasis pathogenesis and treatment. Br J Dermatol. 2021;184(1):14-24.
1. He H, Del Duca E, Diaz A, et al. Mild atopic dermatitis lacks systemic inflammation and shows reduced nonlesional skin abnormalities. J Allergy Clin Immunol. 2021;147(4):1369-1380.